All In Biotech

NDA 219474 · Acrotech Biopharma

Adquey

Difamilast · Topical · Phosphodiesterase 4 Inhibitor

Novel

CDER novel approval, Feb 12, 2026: To treat mild to moderate atopic dermatitis

Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Feb 12, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

14

9 Phase 3, 0 recruiting

FAERS reports

11

9 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 25, 2026.

ADQUEY is indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis. ADQUEY is a phosphodiesterase 4 inhibitor indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis. (1)

Mechanism: Difamilast is an inhibitor of phosphodiesterase-4 (PDE-4). Difamilast’s inhibition of PDE-4 (a major cyclic adenosine monophosphate (AMP)-metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP and decreased productions of various cytokines and chemokines. However, the specific mechanism(s) by which difamilast exerts its therapeutic action is not well defined.

Therapeutic areas: Immunology and inflammation · Dermatology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 12, 2026 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • ADQUEY · DIFAMILAST 1% · OINTMENT, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Difamilast" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting2
  • blister1
  • chills1
  • cough1
  • cutaneous t-cell lymphoma1
  • dermatitis atopic1
  • eczema herpeticum1
  • eczema nummular1
  • erythema1
  • erythema multiforme1
  • feeding disorder1
  • metapneumovirus bronchitis1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20251
202610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 12 on PubMed

Sponsor: Acrotech Biopharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.